Eli Lilly Corp. Stock
Eli Lilly Corp. Stock
Pros and Cons of Eli Lilly Corp. in the next few years
Pros
Cons
Performance of Eli Lilly Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eli Lilly Corp. | 1.970% | 1.114% | -1.530% | 16.489% | -6.014% | 185.251% | 395.690% |
| Johnson & Johnson | 0.360% | 1.907% | 2.976% | 40.565% | 19.441% | 46.191% | 58.222% |
| AbbVie Inc. | -1.740% | -2.725% | -1.128% | -1.118% | -1.833% | 36.216% | 113.086% |
| BioMarin Pharmaceutical Inc. | -0.160% | -2.735% | 1.546% | -21.321% | 0.629% | -38.980% | -20.181% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Eli Lilly (NYSE: LLY) indicate a robust position within the pharmaceutical industry. With a strong market capitalization of approximately $678 billion, the company exhibits significant revenue and profitability levels, which suggests a well-managed operation with a focus on research and development. However, several key ratios also hint at potential challenges that investors should consider.
When analyzing Eli Lilly's financials in detail, both strengths and weaknesses emerge, providing an overarching view of the company's financial health.
Strong Revenue Performance: Eli Lilly reported a total revenue of approximately $35.93 billion for the trailing twelve months (TTM), showcasing its capability to generate substantial income. This impressive revenue figure is supported by a healthy gross profit of about $21.91 billion, translating to a gross margin of around 61.7%.
Comments